Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | Advances in GvHD management and prophylaxis

Alexandros Spyridonidis • 29 Oct 2022
COSTEM 2022
General Ruxolitinib

Alexandros Spyridonidis, MD, University of Patras, Patras, Greece, provides an overview of the latest developments in the prevention of graft-versus-host disease (GvHD). The approval of numerous treatments including ruxolitinib as well as cellular therapies being assessed in clinical trials will seek to improve outcomes in patients with chronic GvHD. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alexandros Spyridonidis

1:09
Can adding ATG to PTCy further reduce the risk of GvHD?
Alexandros Spyridonidis • 29 Oct 2022
5:41
Lowering the standard TBI dose for alloHSCT in young adult patients with ALL
Alexandros Spyridonidis • 29 Oct 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals